GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Profound Medical Corp (NAS:PROF) » Definitions » COGS-to-Revenue

Profound Medical (Profound Medical) COGS-to-Revenue : 0.34 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Profound Medical COGS-to-Revenue?

Profound Medical's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.64 Mil. Its Revenue for the three months ended in Mar. 2024 was $1.91 Mil.

Profound Medical's COGS to Revenue for the three months ended in Mar. 2024 was 0.34.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Profound Medical's Gross Margin % for the three months ended in Mar. 2024 was 66.44%.


Profound Medical COGS-to-Revenue Historical Data

The historical data trend for Profound Medical's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Profound Medical COGS-to-Revenue Chart

Profound Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.52 0.57 0.55 0.39

Profound Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.34 0.39 0.47 0.34

Profound Medical COGS-to-Revenue Calculation

Profound Medical's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2.817 / 7.199
=0.39

Profound Medical's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.641 / 1.91
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Profound Medical  (NAS:PROF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Profound Medical's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.641 / 1.91
=66.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Profound Medical COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Profound Medical's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Profound Medical (Profound Medical) Business Description

Traded in Other Exchanges
Address
2400 Skymark Avenue, Unit 6, Mississauga, ON, CAN, L4W 5K5
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.